The Tower, Trinity TEC
About Inflazome Ltd.Utilizing the scientific expertise of our founders and advisors, Inflazome is leading the way in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome, which is now thought to drive many chronic inflammatory conditions.
Founder: Matt Cooper and Luke O’Neill
14 articles about Inflazome Ltd.
Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inzomelid is a potent, selective, orally-available, brain-penetrant NLRP3 inflammasome inhibitor intended for treatment of debilitating inflammatory diseases
Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)
Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, announces the successful completion of a Phase I study of Inzomelid, alongside positive results from a Cryopyrin-Associated Periodic Syndrome patient dosed with Inzomelid.
Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study
Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, announces the successful completion of a Phase I study of its investigational drug, Somalix.
Inflazome announces that the United States Patent and Trademark Office and the European Patent Office will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020.
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
3/26/2019Foundations increasingly play a large role in funding basic science both domestically and internationally. Recently, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) granted Dublin and Cambridge, UK-based Inflazome more than $1 million.
Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the clinical development of drugs to treat neurodegenerative diseases
Distinguished scientist with deep expertise in innate immunity and its role in neurodegenerative diseases
12/3/2018Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Industry veteran clinician to lead the clinical development of Inflazome’s pioneering NLRP3 inflammasome inhibitors to treat inflammatory diseases
Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept
Financing led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating
Innovative research was funded by The Michael J. Fox Foundation for Parkinson’s Research and the Shake It Up Australia Foundation
Inflazome today announces the appointment of Prof. Paul Ridker to Inflazome’s Scientific Advisory Board.